Practice Signal
This review helps pharmacists evaluate where subcutaneous continuous levodopa and subcutaneous natalizumab fit in advanced Parkinson disease and multiple sclerosis, and what to monitor when patients transition from oral or intravenous routes.
Subcutaneous continuous drug delivery, whether foslevodopa/foscarbidopa for Parkinson OFF time or subcutaneous natalizumab for multiple sclerosis, offers durable disease control or major operational and experience gains, shifting the pharmacist's role toward infusion-site care, dose reconciliation, and patient selection.
Subcutaneous delivery is expanding across chronic neurologic disease, with foslevodopa/foscarbidopa now the first U.S. Food and Drug Administration (FDA)-approved 24-hour subcutaneous levodopa infusion for motor fluctuations and subcutaneous natalizumab established as an alternative to intravenous (IV) dosing in relapsing-remitting multiple sclerosis (RRMS). For advanced Parkinson disease (APD), continuous subcutaneous infusion (CSCI) durably reduces OFF time; for multiple sclerosis (MS), the subcutaneous (SC) route is an efficiency and experience play rather than an efficacy change. Both bodies of evidence are low-certainty and observational but internally consistent.
The APD data extend prior randomized controlled trial (RCT) meta-analyses (near 1.98-hour OFF reduction) into real-world durability, with ND0612 sustaining a 2.81-hour OFF reduction to 36 months (BeyoND extension) and ABBV-951 (foslevodopa/foscarbidopa) reaching a 3.5-hour reduction at 52 weeks (Aldred et al). On the MS side, multicenter Italian economic analyses build on the NOVA phase IIIb crossover and SISTER observational study to quantify large operational and cost savings from switching IV to SC natalizumab.
No single society guideline mandates a specific route for either therapy; the APD findings reinforce the continuous dopaminergic stimulation paradigm that underpins device-aided therapy selection alongside deep brain stimulation (DBS) and levodopa-carbidopa intestinal gel (LCIG), while both IV and SC natalizumab carry equivalent regulatory approval from the European Medicines Agency (EMA) and Agenzia Italiana del Farmaco (AIFA). Guidance therefore leaves route selection to clinical judgment, and the newer evidence supports SC options without displacing existing frameworks. Formulary positioning for foslevodopa/foscarbidopa is anchored in its October 2024 FDA approval.
| Source | Key finding | Grade / Verdict |
|---|---|---|
|
Subcutaneous levodopa infusions cut OFF time in advanced Parkinson disease
Study
real-world durability evidence Confirms subcutaneous levodopa infusion durably reduces OFF time by roughly 2 to 3.5 hours and details infusion-site and neuropsychiatric monitoring priorities.
|
ND0612 sustained a mean 2.81-hour OFF reduction to 36 months (n = 214) | Grade: Low Confirmatory |
|
Subcutaneous Levodopa Infusion Cuts OFF Time in Real-World Parkinson Care
Study · Medicine
concordant real-world confirmation Reinforces the OFF-time and quality-of-life benefit of subcutaneous levodopa and adds titration and patient-selection nuance including BMI-related timing.
|
Daily OFF time reduced by approximately 2.0 to 3.5 hours, with quality-of-life gains of 5.6 to 10.8 points exceeding the 4.72-point minimal clinically important difference | Grade: Low Confirmatory |
|
Subcutaneous Natalizumab Cuts Chair Time, Cost, Boosts Quality of Life
Study · Journal of Neurology
operational and economic evidence Establishes large operational, cost, and patient-experience advantages of SC over IV natalizumab without addressing relative efficacy or safety.
|
SC natalizumab cut infusion chair time by 74% (−82.5 minutes; 95% CI −92.4 to −72.7) and MS center cost by approximately 60% | Grade: Low Confirmatory |
Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.
Become a Subscriber →